MedTrace Logo

Effect of Supplemental Oxygen Therapy on Neurocognitive Performance in Healthy Highlanders

NCT07651917 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-06-16

No results posted yet for this study

Summary

Exposure to high altitudes, defined as locations above 2500 m, has been shown to cause cognitive alternations due to reduced blood oxygenation (SpO2). However, it remains to be determined whether cognitive changes are present in highlanders living at moderate altitudes (2500 m) and whether cognitive alterations are reversible with supplemental oxygen therapy (SOT).

Conditions

  • Neurocognition

Interventions

DRUG

Supplemental oxygen therapy

5 L/min supplemental oxygen therapy administered through nasal canula.

OTHER

Sham intervention

5 L/min sham intervention administered through nasal canula.

Sponsors & Collaborators

  • National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov

    collaborator OTHER_GOV

  • University of Zurich

    lead OTHER

Principal Investigators

  • Michael Furian · University of Zurich

  • Edith M Schneider, Dr. · University of Zurich

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-06-18
Primary Completion
2026-07-31
Completion
2026-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07651917 on ClinicalTrials.gov